Riga Eastern Clinical University Hospital

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis2 trials

Phase

• Phase 32 trials

Status

• Completed2 trials

Lead sponsor

• Eli Lilly and Company2 trials

Closed trials

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source